Keymed Biosciences (HKG:2162) raised net proceeds of HK$853.8 million through a top-up placement, a Thursday Hong Kong bourse filing said.
21.6 million shares were placed by substantial shareholder Moonshot at HK$45.48 apiece to at least six investors.
The biopharmaceutical firm then issued 19 million shares to Moonshot, representing 6.36% of its enlarged issued share capital.
The drug company will use proceeds from the issue for R&D expenses, commercialization of Stapokibart, the capital expenditure of manufacturing and R&D facilities, and general corporate and working capital.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。